Welcome to our dedicated page for AI / ML Innovations news (Ticker: AIMLF), a resource for investors and traders seeking the latest updates and insights on AI / ML Innovations stock.
AI/ML Innovations Inc. develops artificial intelligence and neural-network technology for digital health applications. The company’s platforms use signal processing and deep learning to convert biometric data into clinical insights, with recurring updates centered on ECG analysis, heart rate variability analytics, remote cardiac monitoring, and cardiovascular research support.
News for AIMLF also covers activity at its Neural Cloud Solutions subsidiary, including MaxYield™, CardioYield™, and Insight 360™ commercialization, reseller and distribution agreements, research-services collaborations, medical advisory board appointments, and capital-structure actions such as private placements, convertible debentures, warrants, options, and share issuances for debt settlement.
AI/ML Innovations Inc. (CSE:AIML)(OTCQB:AIMLF) has appointed Dr. Alan Rabinowitz as Chief Medical Officer and Director of Medical Partnerships. Dr. Rabinowitz brings over two decades of experience in clinical cardiology and healthcare strategy, currently serving as Clinical Associate Professor in Cardiology at UBC and previously as Director of the Coronary Care Unit at St. Paul's Hospital.
Dr. Rabinowitz's expertise spans entrepreneurial ventures in advanced diagnostics and personalized medicine, with a focus on integrating artificial intelligence in cardiology. He holds a medical degree from the University of Cape Town, with specializations from the University of Toronto and UBC.
The company also announced a stock option grant of 400,000 shares at $0.105 per share to an officer, vesting quarterly over two years. AIML focuses on AI and machine learning in digital health through various subsidiaries and partnerships, including Quantum Sciences, NeuralCloud Solutions, Health Gauge, Tech2Heal, and AI Rx.
AI/ML Innovations Inc. (CSE:AIML)(OTCQB:AIMLF) has announced significant changes to its Board of Directors. Mark Orsmond, a veteran healthcare executive with over 30 years of experience, has been appointed as Executive Chair. Orsmond's track record includes successfully developing and selling three healthcare businesses to Well Health Technologies Corp., and serving as CFO and Executive VP at Corix Group and ALL-SEA Group.
Michael Nemirow joins as Director, bringing extensive entrepreneurial experience, notably as CEO of Greenstar Plant Products, which he led to global expansion before its acquisition by a U.S. public company in 2021. The company has also granted stock options to a director for 250,000 shares at $0.17 per share, vesting quarterly over one year.
Tim Daniels will step down as Executive Chairman but remain on the Board. These appointments align with AIML's focus on AI and machine learning in digital health and wellbeing solutions.
AI/ML Innovations Inc. (AIML) has appointed Peter Kendall as President and Chief Commercialization Officer, effective January 6, 2025. Kendall, with extensive experience at TELUS Health, Medisys, Lifemark, and 3M, brings expertise in revenue generation and strategic planning across Canada, US, and Europe.
The appointment includes a compensation package featuring a $120,000 signing bonus payable in company shares ($60,000 at appointment and $60,000 after two years), with shares issued at $0.145 or fair market value (minimum $0.05). Additionally, Kendall received 2.5 million stock options at $0.145 per share, vesting in three installments over 12 months.
AIML focuses on AI and machine learning in digital health, owning Quantum Sciences , NeuralCloud Solutions Inc., and holding majority stakes in Health Gauge (70%), AI Rx Inc. (70%), and a 22% commitment in Tech2Heal.
AI/ML Innovations (AIMLF) has completed the acquisition of Quantum Sciences , a company specializing in AI-driven digital healthcare solutions. The acquisition, valued at $750,000, was executed through the issuance of 10 million company shares at $0.075 per share.
Quantum's focus includes developing technologies for cardiovascular disease, neurodegenerative disorders, and metabolic conditions. The company has spent two years designing software to improve patient health management through a centralized information system.
The acquisition brings together AI/ML's signal processing capabilities with Quantum's experienced medical team, including notable cardiologists Dr. Alan Rabinowitz, Dr. Marc W. Deyell, and Dr. Brett Heilbron from St. Paul's Hospital. The shares issued are subject to trading restrictions and voluntary escrow conditions.
AI/ML Innovations Inc. (CSE:AIML)(OTCQB:AIMLF) has completed a shares for debt transaction with one arm's length creditor. The company issued 302,891 shares at a deemed price of $0.08 per share to settle a debt of US$17,260 (CAD $24,231.31) for services rendered. The issued shares are subject to a four-month hold period.
Additionally, the company clarified that warrants issued in connection with a previous private placement from August 19, 2024, involving 7,845,000 units, have a three-year term instead of the initially announced two-year term. Warrant holders who received two-year warrants have been issued revised three-year replacement warrants.
AI/ML Innovations Inc. (CSE:AIML)(OTCQB:AIMLF) has announced a share purchase agreement to acquire Quantum Sciences , a company focused on developing digital healthcare solutions using AI, machine learning, and quantum-inspired methodologies. The acquisition is valued at $690,000, to be paid through the issuance of 10 million common shares at $0.069 per share, reflecting a 25% discount to the 20-day VWAP on the CSE.
Quantum specializes in developing products and services that enhance healthcare trajectories and workflow efficiency through meaningful patient and care provider participation. The transaction is subject to CSE approval and customary closing conditions, with no new control persons being created and no significant debt being assumed.
AI/ML Innovations Inc. (AIMLF) has announced key leadership changes and a debt settlement arrangement. The company appointed Terence Lee, a CPA with 11 years of finance experience, as Chief Financial Officer, replacing Tim Daniels who remains on the Board. Kendra Low, an experienced governance professional with over 20 years of experience, joins as Corporate Secretary.
The company granted 1,250,000 stock options to officers at an exercise price of $0.09 per share, expiring in five years. Additionally, AI/ML entered a debt settlement agreement to convert US$17,260 of debt into 302,891 shares at $0.08 per share, subject to regulatory approval.
AI/ML Innovations Inc. (CSE:AIML)(OTCQB:AIMLF) has announced the re-appointment of Follow The Money Investment Group (FTMIG) as its marketing consultant. FTMIG, based in Hampton, Ontario, will help increase company awareness through various market communications initiatives, including media distribution across multiple online channels such as their website, social media platforms, and Reddit advertisements.
The 12-month engagement began on November 25, 2024, with a fee of $32,500 plus direct expenses, to be paid from general corporate funds. FTMIG's representative Karl Boyd will lead the services from Hampton, Ontario.
AI/ML Innovations Inc. (CSE:AIML)(OTCQB:AIMLF) has completed its non-brokered private placement, raising a total of $2,872,289.94. The final tranche consisted of 24,500,615 Units at $0.065 per Unit, generating $1,592,539.98. Each Unit includes one Common Share and a two-year Warrant exercisable at $0.15 per share. The Company paid $76,032.90 in finder's fees and issued 1,169,737 broker warrants. Three insiders participated with 6,650,000 Units. The proceeds will be used for working capital requirements. Securities issued have a four-month trading restriction until March 27, 2025.
AI/ML Innovations Inc. (CSE:AIML)(OTCQB:AIMLF) has completed the initial closing of its non-brokered private placement, raising $1,279,750 through the issuance of 19,688,461 Shares and Warrants. Each Unit consists of one Common Share and one Warrant, exercisable at $0.15 per share for two years. The company paid $44,070 in finder's fees and issued 504,000 broker warrants. Two company officers subscribed for 11.2% of the Units, while an insider controlling over 10% of shares subscribed for 35.5%. The proceeds will be used for working capital requirements.